Stockscreener 앱 받기
37.48
0.79%
-0.30
전일 마감가:
$37.78
열려 있는:
$37.8
하루 거래량:
272.08K
Relative Volume:
0.47
시가총액:
$680.31M
수익:
$116.88M
순이익/손실:
$-25.09M
주가수익비율:
-267.71
EPS:
-0.14
순현금흐름:
$-20.74M
1주 성능:
-8.23%
1개월 성능:
-10.80%
6개월 성능:
+94.40%
1년 성능:
+116.02%
1일 변동 폭
$37.20
$38.49
1주일 범위
$37.00
$41.70
52주 변동 폭
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
37.48 | 685.76M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance - simplywall.st
Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 - Insider Monkey
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? - Yahoo Finance
Precision Trading with Rigel Pharmaceuticals Inc. (RIGL) Risk Zones - Stock Traders Daily
New leukemia drug combo enters trial for patients with hard-to-treat AML - Stock Titan
HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings - MarketBeat
Rigel Pharmaceuticals price target raised to $71 from $69 at Citi - TipRanks
10 Best Performing Affordable Stocks Under $40 - Insider Monkey
A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance - Yahoo Finance
Equities Analysts Issue Forecasts for RIGL FY2025 Earnings - MarketBeat
Will Rigel Pharmaceuticals Inc stock outperform tech sector in 2025Gap Down & Low Drawdown Trading Strategies - Bộ Nội Vụ
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed? - simplywall.st
Rigel Announces Strong Preliminary 2025 Results and Outlook - TipRanks
Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Impressive Financial Results - GuruFocus
Rigel (RIGL) Projects Strong Revenue Growth for 2025 - GuruFocus
Rigel Provides Business Update and 2026 Outlook - marketscreener.com
Rigel Provides Business Update and 2026 Outlook – Company Announcement - Financial Times
Why Rigel Pharmaceuticals Inc. stock is popular among millennials2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 5.3%Here's What Happened - MarketBeat
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Rigel Pharmaceuticals, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Earnings Risk: Will Rigel Pharmaceuticals Inc. (RI2) stock gain from green policies2025 Price Momentum & Expert Approved Momentum Ideas - Улправда
Is Rigel Pharmaceuticals Inc. stock a buy in volatile markets2025 Major Catalysts & Long-Term Growth Stock Strategies - Улправда
Is Rigel Pharmaceuticals Inc. stock supported by strong cash flows2025 Support & Resistance & Real-Time Sentiment Analysis - ulpravda.ru
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt? - simplywall.st
Rigel Pharmaceuticals, Inc. (RIGL) Investor Outlook: Strong Revenue Growth and Promising Upside - DirectorsTalk Interviews
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio - The Manila Times
SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030Rigel Pharmaceuticals Lea - PharmiWeb.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading 8.4% HigherStill a Buy? - MarketBeat
About Us - FinancialContent
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference - StreetInsider
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Rating Upgraded by Zacks Research - MarketBeat
Best Momentum Stocks to Buy for January 6th - Yahoo Finance
Why Analysts Say The Rigel Pharmaceuticals (RIGL) Story Is Shifting After Q3 And 2025 Guidance - Yahoo Finance
Technical Reactions to RIGL Trends in Macro Strategies - Stock Traders Daily
Is Rigel Pharmaceuticals Inc. stock near bottom after decline2025 Year in Review & Growth Focused Entry Reports - moha.gov.vn
What analysts say about Rigel Pharmaceuticals Inc RI2 stockLow Beta Stocks & Low Risk Investment Growth - earlytimes.in
Jhandewalas Foods Limited Earnings Review What Investors Need to KnowHigh Dividend Yield Stocks & See Risk Factors Before Making Any Move - earlytimes.in
Rigel Pharma: Formulating A Game Plan For 2026 - Seeking Alpha
Rigel Pharmaceuticals, Inc. $RIGL Shares Sold by Voya Investment Management LLC - MarketBeat
Pacer Advisors Inc. Buys New Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Range Financial Group LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) CFO reports multiple option exercises and share ownership - Stock Titan
Rigel Pharmaceuticals: Formulating A Game Plan For 2026 (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):